08:21 AM EST, 11/19/2025 (MT Newswires) -- Avicanna ( AVCNF ) Wednesday announced positive preclinical results and the filing of a U.S. provisional patent application for its powder drug delivery system (PwdRx) platform.

The drug delivery platform addresses key formulation challenges associated with highly lipophilic cannabinoids (CBD, CBG, THC and CBN), which often exhibit poor water solubility, low and variable bioavailability, and delayed onset of action.

Recent in-vitro study of the PwdRx technology demonstrated statistically significant results including 74% higher bioavailability, 63% faster peak plasma levels and a 134% higher peak plasma concentration when compared to medium chain trigylercides (MCT) oil formulation.

"By improving dispersion, solubility and consistency of uptake, the PwdRx platform has the potential to enable health care providers greater flexibility to tailor potential treatment options for patients managing conditions associated with pain and inflammation," said Dr. Karolina Urban, the company's head of medical and sScientific affairs. "We are encouraged by the data and look forward to further advancing the technology into our pharmaceutical pipeline and for further clinical evaluation."

The provisional patent filing covers the composition, methods of use, and potential utility of the PwdRx platform in pain and inflammation, a statement said.